Information Provided By:
Fly News Breaks for October 8, 2018
LOXO
Oct 8, 2018 | 13:15 EDT
As previously reported, IFS Securities analyst David Bouchey upgraded Loxo Oncology to Outperform from Market Perform, with $190 price target, after the company reported updated results from its Phase I/II trial for LOXO-292. The analyst believes the response rates for LOXO-292 continue to look "very strong," the safety data is "excellent" and early results show that these responses appear durable. So far, the drug has outperformed expectations, he adds.
News For LOXO From the Last 2 Days
There are no results for your query LOXO